Triumeq is a fixed-dose tablet containing 50mg of dolutegravir, 600mg of abacavir and 300mg of lamivudine. Triumeq is manufactured by ViiV Healthcare.

Dolutegravir is an HIV integrase inhibitor also marketed alone as Tivicay. Abacavir and lamivudine are nucleoside reverse transcriptase inhibitors also marketed as the fixed-dose combination Kivexa or singly as Ziagen and Epivir. These drugs reduce the amount of HIV in the body and prevent the development of AIDS-defining illnesses.

Triumeq is approved for use in adults and adolescents over the age of 12. Triumeq received marketing approval in the European Union in September 2014 and US marketing approval in August 2014.

Triumeq is dosed as one purple tablet once daily, with or without food.

Triumeq contains abacavir, which is associated with a risk of life-threatening hypersensitivity reaction in a small minority of people with a specific genetic profile. Everyone should undergo a genetic test to rule out potential abacavir hypersensitivity before starting this combination. See abacavir for further information on the symptoms of abacavir hypersensitivity and screening for hypersensitivity.

For more information on Triumeq’s component drugs, including further details of potential side-effects, efficacy and drug resistance, see dolutegravir, abacavir and lamivudine.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.